Solaire Naturals Herbal Fibre (capsule)
Solaire Naturals Herbal Fibre (capsule), NPN 80066794: natural health product licensed in Canada. Medicinal ingredients: Foeniculum vulgare subsp. vulgare var. vulgare, Plantago ovata, Rheum officinale, Juglans nigra.
If this product were sold in France
- Legal conditions
Foeniculum vulgare Mill.: La portion journalière recommandée ne doit pas conduire à une ingestion d'estragole supérieure à 0,05 mg/kg de poids corporel pour les enfants de moins de 12 ans.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Legal conditions
Rheum officinale Baill.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Foeniculum vulgare subsp. vulgare var. vulgare Source : Graine(s) | 21 mg | Not calculated |
| Plantago ovata Source : Enveloppe | 350 mg | Not calculated |
| Rheum officinale Source : Racine | 70 mg | Not calculated |
| Juglans nigra Source : Unripe hulls | 70 mg | Not calculated |
| Réglisse déglycyrrhizinée Source : Racine Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 77 mg | 19.25 mg | Not calculated |
| Juglans cinerea Source : Écorce âgée | 70 mg | Not calculated |
| Taraxacum officinale Source : Racine | 42 mg | Not calculated |
Non-medicinal ingredients
Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 5 Capsule | 2 Tous les jours |
Uses authorised in Canada
Stimulant laxative. Short-term relief of occasional constipation. Promotes bowel movement ( by direct action on the large intestine ringworm (Tinea corporis).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Known Adverse Reactions
Hypersensitivity, such as allergy, has been known to occur following inhaled and/or ingested psyllium; in which case, discontinue use. May cause temporary gas and/or bloating. Reduce dose or discontinue use if you have experience abdominal pain, cramps, spasms and/or diarrhoea.
- Contra-Indications
Do not use if you are experiencing a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative product. Do not use if you have diabetes mellitus in which blood sugar is difficult to regulate. Do not use if you have difficulty swallowing. Do not use if you are allergic to anethole or plants of the Apiaceae/Carrot family. Do not use if you are pregnant or breastfeeding. Do not use if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease such as Crohn's disease or ulcerative colitis, abdominal pain of unknown origin, severe dehydration with depleted water or electrolytes or diarrhoea.
Product record
- Licence holder
- G. Batte Enterprises Inc.
- NPN or DIN-HM
- 80066794
- Status
- Active licence
- Licence date
- 5 February 2016
- Revision date
- 30 March 2016
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80066794
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Foeniculum vulgare subsp. vulgare var. vulgare
Read the warning, when it applies and the studies cited
BITTER FENNEL- FOENICULUM VULGARE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).
Sources cited by Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Condition of application: Essential oil and Tincture.
Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).
Sources cited by Health Canada (1)
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).
Sources cited by Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Health Canada monograph dated 29 November 2024
SWEET FENNEL -FOENICULUM VULGARE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).
Sources cited by Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2024).
Sources cited by Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Solaire Naturals Herbal Fibre (capsule) (G. Batte Enterprises Inc.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80066794-solaire-naturals-herbal-fibre-capsule, updated 30 March 2016.